List of Excipients in Branded Drug DYNA-HEX 4

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	DYNA-HEX 4	chlorhexidine gluconate	0116-1060	COCO DIETHANOLAMIDE
Xttrium Laboratories Inc	DYNA-HEX 4	chlorhexidine gluconate	0116-1060	GLUCONOLACTONE
Xttrium Laboratories Inc	DYNA-HEX 4	chlorhexidine gluconate	0116-1060	HYDROXYETHYL CELLULOSE

Last updated: August 14, 2026

DYNA-HEX 4 is a 4% chlorhexidine gluconate (CHG) topical antiseptic cleanser. Its commercial value depends less on the active ingredient, which is widely available, and more on excipient compatibility, skin tolerability, foam and rinse performance, packaging, hospital procurement, and regulatory control of antimicrobial claims. The strongest opportunities are fragrance-free sensitive-skin variants, low-residue formulations, ready-to-use surgical-prep systems, and institutional private-label supply.

DYNA-HEX 4 Excipient Strategy and Commercial Opportunities

What is DYNA-HEX 4 and how is it regulated?

DYNA-HEX 4 is a topical antiseptic cleanser containing 4% chlorhexidine gluconate. The product is positioned for healthcare skin cleansing and surgical hand or patient preparation applications. CHG is a cationic bisbiguanide antiseptic with broad activity against many Gram-positive and Gram-negative bacteria.

The product sits within the U.S. FDA regulatory framework for topical antiseptic drug products. Its commercial positioning is affected by FDA requirements for:

• Active-ingredient concentration and identity
• Antimicrobial performance
• Product labeling and warnings
• Skin irritation and sensitization
• Manufacturing controls
• Packaging compatibility
• Claims concerning healthcare personnel hand antisepsis, patient preoperative skin preparation, or general skin cleansing

CHG products have received heightened FDA scrutiny because of allergic reactions, including rare anaphylactic reactions, and because FDA has required additional safety and efficacy support for certain healthcare antiseptic uses.[1][2]

Product classification and commercial implications

Attribute	DYNA-HEX 4 assessment
Active ingredient	Chlorhexidine gluconate
Strength	4%
Dosage form	Topical liquid cleanser or scrub
Primary market	Hospitals, surgery centers, clinics, institutional healthcare
Likely regulatory category	OTC topical antiseptic drug product
Key commercial differentiators	Foam, rinseability, skin feel, fragrance, residue, packaging, price
Principal safety issue	CHG hypersensitivity and eye, ear, mucosal, and neonatal exposure
Primary competitive products	Hibiclens, ChloraPrep, generic CHG scrubs, CHG-impregnated cloths

The product is not a small-molecule prescription medicine with conventional Orange Book patent dynamics. Its commercial protection is more likely to arise from formulation know-how, packaging, trademarks, manufacturing scale, institutional contracts, and regulatory execution.

Which excipients are strategically important in a 4% CHG formulation?

The optimal excipient system must preserve CHG activity while delivering acceptable foam, wetting, rinseability, viscosity, odor, and skin tolerability. The formulation should avoid components that bind, precipitate, neutralize, or otherwise reduce the availability of the cationic CHG molecule.

Surfactants

Surfactants control wetting, soil removal, foam, and rinse behavior. They are the most commercially important excipient class after the active ingredient.

Suitable systems generally favor nonionic or amphoteric surfactants. Candidate technologies include:

• Amphoteric betaines for mildness and foam
• Nonionic surfactants for soil removal and compatibility
• Low-irritancy foam boosters
• Sulfate-free systems for sensitive-skin positioning

Anionic surfactants require particular caution. CHG can interact with negatively charged materials, including soaps and anionic detergents. These interactions may reduce antimicrobial activity or produce incompatibility in the finished product.[3]

The key development target is not maximum foam. Excessive foam can increase rinse time, leave residue, complicate surgical preparation, and raise water consumption in hospitals.

Humectants and skin-conditioning agents

Humectants can reduce the drying effect associated with repeated antiseptic washing. Glycerin is a conventional option, although high concentrations can increase tackiness and slow rinsing.

Potential conditioning strategies include:

• Glycerin at a controlled level
• Propanediol or similar low-tack humectants
• Mild emollient systems
• Skin-barrier support ingredients with demonstrated CHG compatibility

The commercial trade-off is clear: stronger skin-conditioning claims can improve adoption among nurses and surgeons, but added excipients increase stability, preservative, and regulatory complexity.

Viscosity modifiers

Viscosity affects dosing, spreadability, bottle handling, pump performance, and perceived quality. A formulation that is too thin can appear commoditized and dispense inefficiently. A formulation that is too thick can retain product on skin, increase rinse burden, and cause packaging failures.

Viscosity modifiers should be evaluated for:

• Compatibility with CHG
• Electrolyte sensitivity
• Temperature stability
• Pump and cap performance
• Lack of microbial growth support
• Rinseability under hospital conditions

Polymeric thickeners can interact with cationic actives. Each candidate requires testing for assay recovery, antimicrobial performance, clarity, phase stability, and viscosity drift.

pH control

pH affects skin tolerability, chemical stability, preservative performance, and surfactant behavior. The formulation should use a controlled, skin-compatible pH range rather than treating pH only as a manufacturing parameter.

Potential risks include:

• Precipitation from unsuitable buffers
• Reduced CHG stability
• Increased irritation
• Interaction with packaging components
• Changes in viscosity or fragrance profile

A minimal-buffer strategy may offer the strongest commercial position if it maintains stability without adding unnecessary ionic components.

Fragrance and color

Fragrance and color are low-value excipients with high downside risk in institutional healthcare.

Fragrance can improve consumer acceptability in retail channels but may be undesirable in operating rooms, intensive-care units, oncology settings, and facilities with fragrance-sensitivity policies. Dyes can create staining concerns and increase the number of formulation variables.

A portfolio strategy should separate:

1. Fragranced retail or general-care product
2. Fragrance-free institutional product
3. Dye-free sensitive-skin product
4. Premium product with documented low-residue performance

The fragrance-free and dye-free variants offer stronger medical-market differentiation than additional fragrance options.

What excipient incompatibilities create the greatest technical risk?

CHG is cationic. The most important compatibility risks involve anionic substances, reactive packaging materials, and ingredients that alter surface deposition.

High-priority incompatibility categories

Risk category	Potential consequence
Anionic surfactants or soaps	Reduced available CHG or precipitation
Anionic polymers	Loss of assay, haze, reduced antimicrobial activity
High ionic load	Stability or viscosity changes
Reactive packaging materials	Adsorption, discoloration, extractables
Fragrance components	Irritation, odor drift, assay or stability effects
Dyes and pigments	Staining, migration, regulatory complexity
Excess humectant	Tackiness and slow rinse
Aggressive preservatives	Skin irritation or incompatibility

CHG activity testing should be performed in the final formulation, not inferred from the active ingredient alone. Testing should include neutralization controls because residual CHG can distort microbiological results.

The development package should include accelerated and long-term stability, antimicrobial effectiveness, preservative performance where applicable, container-closure compatibility, freeze-thaw testing, pump delivery, and repeated-use simulation.

What formulations are protected by patents or proprietary know-how?

Publicly visible commercial protection for CHG scrub products is generally less likely to depend on a single blocking composition patent than on accumulated formulation and manufacturing know-how.

Potentially protectable areas include:

• A low-irritancy surfactant combination
• A low-residue 4% CHG formulation
• A specific foam profile or dispensing system
• A stable fragrance-free composition
• A CHG formulation with improved rinseability
• A dual-chamber package separating incompatible components
• A ready-to-use applicator or preoperative preparation system
• A process that controls CHG particle formation or adsorption
• A packaging system that limits active loss
• A formulation optimized for automated hospital dispensing

The strongest practical IP position would combine a narrow composition claim with process, packaging, and use claims. A formulation patent that covers only conventional CHG, water, glycerin, and surfactant components would face substantial validity and design-around pressure.

Because DYNA-HEX 4 is a branded topical antiseptic rather than an innovative molecular entity, trademark, supply reliability, hospital contracts, and manufacturing cost are likely to be more important than Orange Book-listed patent exclusivity.

How strong is the DYNA-HEX 4 patent estate?

The patent estate should be treated as potentially modest unless the product is supported by proprietary formulation, delivery, or packaging patents.

Protection category	Likely relevance to DYNA-HEX 4
Active-ingredient patent	Low; CHG is an established antiseptic
Basic 4% CHG composition	Limited unless narrowly differentiated
Surfactant system	Moderate if unexpected compatibility or tolerability is demonstrated
Packaging and dispensing	Moderate to high for differentiated systems
Manufacturing process	Moderate; may be difficult to detect externally
Method-of-use claims	Limited by established antiseptic uses and regulatory claim requirements
Trademark and trade dress	Commercially relevant
Trade secret formulation know-how	Potentially important
Orange Book exclusivity	Generally not the principal protection mechanism

Paragraph IV litigation is not the central generic-entry pathway for a conventional OTC CHG cleanser unless the product is tied to an approved application with listed patents. Competition is more likely to arise through OTC monograph compliance, private-label manufacturing, state procurement, and retailer substitution.

What commercial opportunities exist for DYNA-HEX 4 excipient innovation?

Fragrance-free and dye-free institutional formulation

Hospitals increasingly favor products that reduce occupational exposure, residue, odor, and patient discomfort. A fragrance-free, dye-free DYNA-HEX 4 variant could target operating rooms, intensive-care units, oncology departments, and long-term-care facilities.

The value proposition is operational rather than cosmetic:

• Lower odor burden
• Reduced risk of fragrance-related complaints
• Easier institutional standardization
• Better fit with sensitive-skin protocols
• Potentially improved acceptance for repeated healthcare-worker use

Low-residue and rapid-rinse product

A low-residue formulation could compete on water use, preparation time, and user satisfaction. The product should be assessed for residual CHG deposition because persistent skin activity can be commercially valuable, but excessive residue may create a negative user experience.

A defensible product claim would require comparative testing against leading CHG scrubs under standardized wash and rinse conditions.

Premium skin-tolerability platform

A product with controlled humectancy and mild surfactants could target facilities where dermatitis and repeated washing affect employee compliance. The formulation should avoid unsupported therapeutic or dermatological claims. Regulatory labeling would need to distinguish cosmetic skin feel from drug claims.

Ready-to-use surgical preparation

The largest adjacent opportunity is a preoperative preparation platform rather than a bottle-only cleanser. Possible formats include:

• Single-use sponge applicators
• Metered-dose pump systems
• Foam dispensers
• Unit-dose hospital packs
• Procedure-specific kits
• CHG-compatible applicators with controlled coverage

These formats can increase average selling price and create switching costs through supply contracts and workflow integration.

Private-label and contract-manufacturing expansion

The underlying technology is suitable for private-label hospital systems, ambulatory surgery centers, and regional distributors. A manufacturer with validated CHG formulation and packaging capabilities could offer:

• Standard 4% CHG scrub
• Fragrance-free version
• Dye-free version
• Premium skin-conditioning version
• Institutional bulk packaging
• Unit-dose or procedure kits

The main commercial barrier is not active-ingredient access. It is consistent quality, regulatory documentation, supply continuity, and procurement qualification.

How does DYNA-HEX 4 compare with competing CHG products?

Product category	Main differentiation	Excipient opportunity
4% CHG liquid scrub	Familiarity and low unit cost	Better foam, rinse, skin feel
2% CHG cloth	Convenience and standardized application	Moisture retention, preservative system, packaging
Alcohol-based CHG prep	Rapid antimicrobial activity and surgical use	Solvent compatibility, drying control, flammability management
Iodophor scrub	Alternative antiseptic mechanism	Reduced staining, skin tolerance
Generic CHG cleanser	Price and availability	Private label, procurement efficiency
Premium CHG formulation	User experience and institutional fit	Low residue, fragrance-free, skin conditioning

DYNA-HEX 4 is most exposed to generic and private-label competition in standard liquid scrub. It can defend pricing more effectively through differentiated packaging, validated user performance, and hospital-specific supply programs.

What FDA and market-entry issues affect new DYNA-HEX 4 variants?

A reformulated product must maintain the applicable active ingredient, concentration, labeling, manufacturing controls, and performance profile. Changes to surfactants, preservatives, fragrance, color, viscosity, or packaging may require a revised regulatory assessment.

High-risk claims include statements that imply:

• Prevention of surgical-site infection
• Treatment of infection
• Superiority over competing antiseptics
• Long-lasting protection beyond supported data
• Use on populations with specific medical conditions
• Safe use in neonates or premature infants

The product label must maintain appropriate warnings concerning eyes, ears, mucous membranes, damaged skin, and allergic reactions. FDA has specifically addressed serious hypersensitivity concerns involving CHG-containing products.[2]

What generic-entry risks exist for DYNA-HEX 4?

Generic-entry risk is high for the base 4% CHG cleanser because:

• CHG is an established active ingredient
• The dosage form is technically straightforward
• Multiple contract manufacturers can produce topical cleansers
• Hospitals often procure by specification and price
• Retail and institutional buyers can substitute equivalent products

Risk is lower for differentiated formats that require:

• Validated packaging
• Specialized applicators
• Demonstrated low-residue performance
• Proprietary surfactant systems
• Integrated hospital distribution
• Procedure-specific kits

The most defensible commercial strategy is therefore a product platform rather than a single bottle formulation.

Key Takeaways

• DYNA-HEX 4 is a 4% chlorhexidine gluconate topical antiseptic cleanser.
• Excipient selection must prioritize CHG compatibility because the active is cationic and can interact with anionic materials.
• Surfactants, viscosity modifiers, humectants, fragrance, dye, pH control, and packaging determine product performance.
• The strongest near-term opportunities are fragrance-free, dye-free, low-residue, skin-tolerant, and ready-to-use formats.
• Conventional 4% CHG scrub is vulnerable to generic and private-label substitution.
• Formulation, packaging, dispensing, and manufacturing-process patents are more commercially relevant than basic CHG composition patents.
• FDA safety requirements, especially CHG hypersensitivity warnings, materially affect labeling and market positioning.
• Hospital contracts, supply reliability, procurement economics, and workflow integration may provide stronger commercial protection than conventional drug exclusivity.

FAQs

Can DYNA-HEX 4 use anionic surfactants?

Anionic surfactants present a compatibility risk because they can interact with cationic chlorhexidine. Nonionic and amphoteric surfactants are generally more attractive starting points, subject to final-formulation testing.

Is a 4% CHG scrub eligible for Orange Book patent protection?

The product is not typically protected like a patented prescription drug with a large Orange Book estate. Commercial protection is more likely to involve trademarks, formulation patents, packaging rights, manufacturing know-how, and institutional contracts.

What is the best premium positioning for DYNA-HEX 4?

A fragrance-free, dye-free, low-residue formulation with controlled foam and improved skin feel offers the clearest premium positioning for hospitals and ambulatory surgical centers.

Can DYNA-HEX 4 be converted into a preoperative applicator?

Yes. A single-use sponge, metered-dose applicator, or procedure kit could increase convenience and average selling price, but the packaging and delivery system would require separate stability, compatibility, performance, and regulatory evaluation.

What is the main commercial weakness of standard DYNA-HEX 4?

The standard liquid 4% CHG scrub is relatively easy for qualified manufacturers to replicate. Without differentiated excipients, packaging, validated performance, or distribution contracts, price-based generic and private-label competition is likely.

References

1. U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptics; topical antimicrobial drug products for over-the-counter human use. Federal Register, 81 Fed. Reg. 61106.

2. U.S. Food and Drug Administration. (2017). FDA strengthens warning that chlorhexidine gluconate can cause rare but serious allergic reactions. https://www.fda.gov

3. European Directorate for the Quality of Medicines & HealthCare. (2023). Chlorhexidine gluconate monograph. In European Pharmacopoeia.

4. U.S. Food and Drug Administration. (2023). OTC Monograph M003: Antiseptic drug products for over-the-counter human use. https://www.accessdata.fda.gov

5. DailyMed. (n.d.). DYNA-HEX 4 chlorhexidine gluconate topical antiseptic product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov